- Amgen Inc (NASDAQ:AMGN) presented data on overall survival from the Phase 2 results of the CodeBreaK 100 clinical study for Lumakras (sotorasib) in previously treated non-small-cell lung cancer (NSCLC) patients.
- Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine.
- The study showed that treatment with Lumakras induced a 37% objective response rate in patients and 12.5 months of median overall survival.
- In the trial, sotorasib demonstrated a median progression-free survival of 6.8 months.
- An additional patient achieved complete response (bringing the total to four complete responses and 42 partial responses) compared to previously reported results.
- Data from a separate study were also presented discussing patient-reported outcomes on Lumakras, which is a once-daily oral medication. Treatment-related adverse events were mostly mild and manageable with care.
- In exploratory analyses, tumor response to Lumakras was consistently observed across a range of biomarker subgroups.
- In the patient subsets separated by baseline PD-L1 expression (n=86), response and tumor shrinkage were observed across the range of baseline PD-L1 expression levels, with a response rate of 48% for the PD-L1 negative group.
- Improved efficacy with Lumakras was seen in the STK11-mutant group with concurrent wild-type KEAP1 (n=22) with median progression-free survival of 11.0 months and median overall survival of 15.3 months.
- Last month, sotorasib received FDA accelerated approval for use in adults with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systematic therapy.
- Price Action: AMGN shares are trading lower by 0.41% at $235.87 on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
